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Abstract
Phenanthroindolizidine-based tylophora alkaloids have been reported to have potential antitumor,
anti-immuno and anti-inflammatory activity. The structure-activity relationships of a series of
tylophora alkaloids were studied to guide future drug design. Our results indicate that although these
compounds are structural analogs, their potency of cytotoxicity, selectivity against NF-κB signaling
pathway, and their inhibitory effects against protein and nucleic acid synthesis are different. Because
they do not have an identical spectrum of targets, the studied compounds are structural, but may not
be functional analogs.
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Tylophora alkaloids originate from various plants of the Asclepiadaceae family, such as
Tylophora, that are native of India and Southeast Asia.1 They have antitumor,2–6 anti-
inflammatory,7 anti-arthritis,8 and anti-lupus activity in vivo.9 Due to their diverse and potent
pharmacological actions, they continue to be targets for synthesis, modification, structure-
activity relationship (SAR) studies since their first isolation in 1935.10 Their molecular
mechanisms of action of antitumor and anti-inflammatory activity include: inhibitory effect
on protein synthesis2 and nucleic acid synthesis,2,11 inhibitory effect on RNA transcription
which are controlled by cyclic AMP response elements (CREs), activator protein-1 (AP-1)
sites, and NF-κB binding sites,6 and ability to suppress the expression of a subset of proteins,
such as cyclin D1, cyclin B1 and CDK4.12 Tylocrebrine, a positional isomer of tylophorine,
was found in clinical trials to have intolerable central nervous system (CNS) side effects. To
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offset such CNS side effects, a series of phenanthrene–based tylophorine derivatives (PBTs)
with increased polarity was synthesized to limit the crossing of the blood-brain barrier.13 It
was assumed that these analogs would have the same mechanism of action and behave as
functional analogs of the tylophora alkaloids.
Previous structure–activity relationships of phenanthroindolizidine alkaloids have concluded
that the rigid phenanthrene structure (Figure 1) on the phenanthrene ring is required to maintain
potent cytotoxicity, and that the lack of an indolizidine ring or the presence of OMe ether at
position 2 leads to the loss of cytotoxicity.14–16 To continue the structure–activity relationship
studies using the tylophora alkaloids rac-cryptopleurine, (−)-antofine, (−)-tylophorine, and (−)-
ficuseptine C recently obtained by a concise and modular total synthesis approach,17 and to
verify whether the synthetic PBT compounds are functional analogs of the tylophora alkaloids,
we compared their cytotoxicity, inhibitory effects on NF-κB, AP-1, CRE and glucocorticoid
response element (GRE), and some of their impact on protein, DNA and RNA synthesis. We
hypothesized that opening of the D-ring would have affect the potency; if the PBT compounds
are functional tylophora alkaloid analogs, they might have comparable effects on the different
intracellular pathways. Phenanthrene-based derivatives PBTs #28 and #31–34 were
synthesized by Dr. K. H. Lee’s group.13 The tested tylophora alkaloids, rac-cryptopleurine,
(−)-antofine, (−)-tylophorine, (−)-ficuseptine C, precursors #1 and precursors #2 were provided
by Dr. Alois Fürstner.17 (+)-S-Tylophorine (DCB-3500) was synthesized by Dr. David C.
Baker’s laboratory. 16
To analyze the structure-activity relationships of tylophora alkaloids, we first compared their
cytotoxicity in HepG2, PANC-1, and CEM cells, followed by the procedures described
previously.6,16 (+)-(S)-tylophorine and (−)-(R)-tylophorine differ only in the absolute
configuration of the chiral center at the 13a position, the (R)-configured compound led to an
approximately 3~4-fold decrease in cytotoxicity (Table 1). The difference in the structures of
(−)-antofine and (−)-(R)-tylophorine is at the R3 position (Figure 1). The absence of an OMe
substituent at R3 led to a 6-fold increase in cytotoxicity in HepG2 cells, and more than 10-fold
increase in cytotoxicity in PANC-1, and CEM cells (Table 1). The structural difference between
(−)-antofine and rac-cryptopleurine lies in the size of the E-ring. The presence of the six-
membered E-ring in the phenanthroquinolizidine skeleton of rac-cryptopleurine led to a 2~4-
fold increase in cytotoxicity in comparison to (−)-antofine which has a five-membered Ering
(1.5±0.2 nM vs. 4.9±0.4 nM in HepG2; 0.5±0.1 nM vs. 2.2±0.3 nM in PANC-1; and 2±0.5 nM
vs. 5.2±0.5 nM in CEM as shown in Table 1). In contrast, precursor #1 and #2 were the least
potent compounds among the tylophora-related alkaloids listed in Table 1. The structural
difference between rac-cryptopleurine and precursor #1 is that the D-ring is formally opened
in precursor #1, which leads to a dramatic decrease of cytotoxicity. For instance, in HepG2
cells, the GI50 value of rac-cryptopleurine is 1.5±0.2 nM, whereas the GI50 value of precursor
#1 is 1723±417 nM. This represents a more than 1000-fold decrease of cytotoxicity. Precursor
#2 represents the bare phenanthrene backbone of the tylophora alkaloids lacking the fused
aliphatic heterocyclic domain. This structural change is not tolerated and results in very poor
cytotoxicity, with a GI50 value of over 10 μM in HepG2 and PANC-1 cells (Table 1). The
difference in the structures of (−)-ficuseptine C and (−)-antofine consists in the replacement
of the OMe groups at R1 and R2 in (−)-antofine by a cyclic methylenedioxy unit in (−)-
ficuseptine C. This structural change resulted in a more than 60-fold decrease of cytotoxicity
in HepG2, PANC-1 and CEM cells (Table 1, compare 371±27 nM vs. 4.9±0.4 nM in HepG2;
156±26 nM vs. 2.2±0.3 nM in PANC-1; and 323±13 nM vs. 5.2±0.5 nM in CEM). Other
phenanthrene-based tylophorine derivatives were designed to increase the polarity as
mentioned previously which was achieved by formal opening of the indolizidine.13 However,
this structural modification dramatically impaired the cytotoxicity. As shown in Table 1 (lower
panel), the GI50s of all PBTs tested is between 1.6 to 8.6 μM in HepG2, PANC-1, and CEM
cells.
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Previously, we had shown that DCB-3503 and its analogs could inhibit NF-κB, CRE and AP-1
mediated transcription, more selectively against NF-κB signaling pathway.6 NF-κB is a family
of transcription factors that play pivotal roles in chronic and acute inflammatory diseases,
autoimmune diseases and different types of cancer.18 Recently, NF-κB and the signaling
pathways that regulate its activity have become a focus of intense drug discovery and
development efforts.18 The potent inhibitory effects of DCB-3503 on NF-κB-mediated
transcription may be one of the mechanisms of its antitumor activity. Here we compared the
effects of the tylophora alkaloids (Figure 1) against NF-κB, CRE, AP-1, and GRE mediated
transcription. HepG2-NF-κB-luc, HepG2-CRE-luc and HepG2-AP-1-luc stable cell lines were
generated as previously described.16 GRE mediated transcription was analyzed by transient
transfection of HepG2 cells with pGRE-luc (Clontech). The IC50 of the inhibitory effect of the
tylophora alkaloids against stimulator induced NF-κB, CRE, AP-1, GRE activity is listed in
Table 2. The IC50 of the inhibitory effect of tylophora alkaloids against endogenous NF-κB,
CRE, AP-1, and GRE mediated transcription is shown in “Supplementary data Table S1”.
Among the four signaling pathways, NF-κB is the most sensitive signaling pathway inhibited
by all the tylophora alkaloids (listed in Table 2, upper panel) except precursor #2. For instance,
the IC50 of (−)-antofine for NF-κB, CRE, AP-1, and GRE are 7.3±1.9 nM, 167±42 nM, 135
±16 nM, and 24±0.5 nM, respectively. NF-κB is about 20-fold more sensitive in terms of
inhibition than CRE and AP-1 pathways. In addition, the rank order of their potency in terms
of NF-κB inhibition was rac-cryptopleurine > (−)-antofine > (+)-(S)-tylophorine > (−)-(R)-
tylophorine > (−)-ficuseptine C > precursor #1 > precursor #2. Similar rank order was observed
in regards to the potency of cytotoxicity (Table 1). The rank order of potency and selectivity
against endogenous NF-κB mediated transcription also had the same trend (Supplementary
data Table 1). In terms of relative activity against different signaling pathways, the tylohora
alkaloids have demonstrated some degree of selectivity. However, the activity of all the PBTs
tested against all the four signaling pathways is very poor, with IC50 of more than 6 μM (Table
2, lower panel). If we calculate the relative ratio of IC50 (Table 2) and GI50 (Table 1, Column
HepG2) for (−)-antofine, the value would be 1.5, 34, 28, and 4.9 for NF-κB, CRE, AP-1 and
GRE respectively. If we apply the same calculation for precursor #1, the value would be 1.3,
7, 5.7, and 2.6 for NF-κB, CRE, AP-1 and GRE respectively. This indicated that (−)-antofine
selectively inhibited NF-κB, whereas precursor #1 showed less selectivity against the four
signaling pathways. These data suggested that the different analogs might act on multiple target
sites, and affect different pathway through different mechanisms.
Early studies in the 1970’s demonstrated that the phenanthrene alkaloid tylocrebrine inhibit
protein and nucleic acid synthesis.11 During our studies of the mechanism of action of the
tylophorine analog DCB-3503, we also observed that this compound could inhibit amino acid
and thymidine, but not uridine incorporation in a time-dependent and dose-dependent manner
(Gao et al, unpublished data). We observed that (−)-ficuseptine C, precursor #1, and PBTs
differ significantly in terms of their cytotoxicities and their potency and selectivity against the
NF-κB signaling pathway (Table 1 and 2); we decided to investigate their effects against
protein, DNA and RNA synthesis, by comparing their effects against L-[35S]-methionine
incorporation into protein, [14C]-thymidine incorporation into DNA, and [14C]-uridine
incorporation into RNA. The experimental procedures are available in “Supplementary data”.
The concentrations tested were based on each analog’s specific cytotoxicity (1/3, 1, 3, and 10
EC50).
As shown in Figure 2A and 2B, both (−)-antofine and (−)-ficuseptine C inhibited DNA and
protein synthesis in a dose-dependent manner. In contrast, (−)-antofine inhibited RNA
synthesis only slightly, whereas (−)-ficuseptine C also inhibited RNA synthesis in a dose-
dependent manner. There are two major structural differences between PBTs and the rest of
the tylophora alkaloids listed in Figure 1: 1) the OMe groups at R1 and R2 are replaced by a
cyclic methylenedioxy moiety; 2) the indolizidine ring of the natural products has been
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formally opened. By comparing the effects of (−)-antofine and (−)-ficuseptine C, the role of
the replacement of the OMe groups at R1 and R2 by a methylenedioxy bridge was clarified.
Therefore our results suggest that the replacement of the OMe ethers at R1 and R2 by a
methylenedioxy moiety significantly changes the compound’s mechanism of action. The major
difference between (−)-antofine and precursor #1 is the opening of D-ring. (−)-ficuseptine C
shares the methylenedioxy motif with the PBTs and has a similar pyrrolidine ring as compound
PBTs #32. Therefore, by comparing the effects of (−)-antofine and precursor #1, and the effects
of (−)-ficuseptine C with those of PBT #32, the effect of opening the indolizidine ring was
clarified. As shown in Figure 2C and 2D, both precursor #1 and PBT #32 inhibited DNA and
RNA synthesis in a dose-dependent manner. In contrast, PBT #32 only sightly inhibited protein
synthesis, whereas precursor #1 also inhibited protein synthesis in a dose-dependent manner.
These results indicate that the formal opening of the D-ring or the indolizidine ring significantly
changes the mechanism of action of these compounds (compare the profile changes between
Figure 2A and 2C, Figure 2B and 2D). In addition, the distinct effects between (−)-antofine
and PBT #32 [(−)-antofine more selectively inhibited protein synthesis, but not RNA synthesis
(Figure 2A), whereas PBT #32 more selectively inhibited RNA synthesis, but not protein
synthesis (Figure 2D)] demonstrate that replacement of the OMe groups at R1 and R2 by a
methylenedioxy unit and the opening of the indolizidine ring totally changes their mechanism
of action. Due to the significantly divergent effects of (−)-antofine, PBT #32, (−)-ficuseptine
C and precursor #1 against protein and nucleic acid synthesis, we conclude that these
compounds, although being structurally fairly close, may not constitute the same class of
compounds in functional terms. The concept of structural analogs with different mechanisms
of action has been reported previously.19,20 Kimball et al. recently described a series of
tylophora analogs derived from Tyloindicine I, operated through an unknown mechanism of
action different from the parental compound.19 Another example is the comparison of
podophyllotoxin and etoposide (VP-16), podophyllotoxin is a potent inhibitor of microtubule
assembly, whereas its derivative etoposide, currently used in clinical treatment of many cancers
such as small cell lung carcinoma and testicular cancer, does not inhibit tubulin polymerization,
but rather acts as an inhibitor of DNA topo-isomerase II, which causes double strand breaks
in DNA.20
In summary, phenanthrene based compounds exhibit pronounced structure-activity
relationships; both the replacement of the OMe ethers at R1 and R2 by a methylenedioxy bridge
(Figure 1) and the opening of the indolizidine ring results in dramatically reduced cytotoxic
potency, whereas the loss of the OMe group at R3 and the replacement of the five-membered
E-ring by a six-membered E-ring significantly increased the observed cytotoxicity. Although
these compounds are close structural analogs, their cytotoxic potency, selectivity against NF-
κB signaling pathway, and their effects against protein, DNA, and RNA synthesis are so
different that they should not be considered as the same class of compounds. That is, various
tylophora alkaloids may be structural but not functional analogs.
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The chemical structures of tylophora alkaloids, and phenanthrene-based tylophorine
derivatives.
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Figure 2. The effects of tylophora alkaloids, and phenanthrene-based tylophorine derivatives on
L-[35S]-methionine, [14C]-thymidine and [14C]-uridine incorporation
HepG2 cells were pretreated with serial dilutions of drugs for 5 min and labeled with L-[35S]-
methionine, [14C]-thymidine or [14C]-uridine, respectively. Their incorporation percentage
(compared with control) was shown. A. HepG2 cells were pretreated with (−)-antofine 1.5 nM,
5 nM, 15 nM and 50 nM, respectively. B. HepG2 cells were pretreated with (−)-ficuseptine C
100 nM, 300 nM, 1 μM and 3 μM, respectively. C. HepG2 cells were pretreated with precursor
#1 0.5 μM 1.5 μM, 5 μM and 15 μM, respectively. D. HepG2 cells were pretreated with PBT
#32 1.5 μM, 5 μM, 15 μM, and 50 μM, respectively. E. Schematic description of the SAR of
tylophora alkaloids and PBTs.
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Table 1










(+)-(S)-tylophorine 11 ± 4b 12 ± 2 15 ± 3
(−)-(R)-tylophorine 33 ± 2 29 ± 6 67 ± 6
(−)-antofine 4.9 ± 0.4 2.2 ± 0.3 5.2 ± 0.5
Rac-cryptopleurine 1.5 ± 0.2 0.5 ± 0.1 2 ± 0.5
precursor #1 1723 ± 417 904 ± 297 567 ± 58
precursor #2 >10000 >10000 >2000










PBT #28 2.3 ± 0.3 2.2 ± 0.3 2.0 ± 0.3
PBT #31 8.6 ± 3.6 7.4 ± 0.3 6.2 ± 0.2
PBT #32 5.4 ± 1.4 6.2 ± 0.7 2.7 ± 0.1
PBT #33 3 ± 0.7 2.3 ± 0.2 1.7 ± 0.3
PBT #34 3.1 ± 1.0 2.3 ± 0.2 1.6 ± 0.5
a
Values are means ± SD of three experiments, with each data point done in triplicate.
b
Published.6
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Table 2
The IC50 of the inhibitory effect of tylophora alkaloids, and PBTs against stimulated NF-κB, CRE, AP-1 and GRE













(+)-S-tylophorine 41 ± 20b >300 b >300 b 229 ± 33
(−)-R-tylophorine 317 ± 51 7910 ± 344 2257 ± 123 534 ± 113
(−)-antofine 7.3 ± 1.9 167± 42 135 ±16 24 ± 0.5
Rac-cryptopleurine 1.4 ± 0.6 25 ± 0.5 18.6 ± 0.8 10 ± 0.2
precursor #1 2171 ± 351 12025 ± 830 9776 ± 625 4500 ± 312
precursor #2 >10000 >15000 >15000 >15000













PBT #28 7.9 ± 1.1 8.6 ± 0.6 8.7 ± 2.1 9.2 ± 1
PBT #31 23.5 ± 2.2 25.0 ± 6 27 ± 4.4 >30
PBT #32 21 ± 0.5 24 ± 0.8 >30 19 ± 4.2
PBT #33 7 ± 0.2 12.1 ± 0.4 6.2 ± 0.3 7.2 ± 1.9
PBT #34 10.2 ± 1.1 18.5 ± 2.1 10 ± 1.8 20.7 ± 2.8
a
Values are means ± SD of three experiments, with each data point done in triplicate.
b
Published.16
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